Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9291 in EGFR Mutant NSCLC
NCT02771314Phase 2Unknown
- Sponsor
- Hellenic Oncology Research Group
- Start
- Aug 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Primary endpoint: Biomarkers of resistance to first and third (AZD9291) generation EGFR TKIs up to 2.5 years. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02771314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771314.